Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination

References

• Etheridge ML, Campbell SA, Erdman AG, et al. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine: NBM. 2013;9(1):1–14.
   PubMed Web of Science ®Google Scholar
• Sainz V, Conniot J, Matos AI, et al. Regulatory aspects on nanomedicines. Biochem Biophys Res Commun. 2015;468:504–510.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853–860.
   PubMed Web of Science ®Google Scholar
• Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med. 2011;365(7):637–646.
   PubMed Web of Science ®Google Scholar
• Buell KG, Chung C, Chaudhry Z, et al. Lifelong antiretroviral therapy or HIV cure: the benefits for the individual patient. AIDS Care. 2015;1–5. doi:10.1080/09540121.2015.1074653
   Web of Science ®Google Scholar
• WHO. HIV/AIDS fact sheet. 2014. [cited 2015 Nov 7]. Available from: http://www.who.int/mediacentre/factsheets/fs360/en/.
   Google Scholar
• Rappuoli R, Aderem AA. 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature. 2011;473(7348):463–469.
   PubMed Web of Science ®Google Scholar
• Johnston MI, Fauci AS. An HIV vaccine—evolving concepts. N Engl J Med. 2007;356(20):2073–2081.
   PubMed Web of Science ®Google Scholar
• Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science. 2002;296(5577):2354–2360.
   PubMed Web of Science ®Google Scholar
• Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384(9939):258–271.
   PubMed Web of Science ®Google Scholar
• McCoy LE, Weiss RA. Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med. 2013;210(2):209–223.
   PubMed Web of Science ®Google Scholar
• Bordon Y. Immunotherapy: checkpoint parley. Nat Rev Cancer. 2015;15(1):3–3.
   Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881–1893.
   PubMed Web of Science ®Google Scholar
• McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis. Lancet. 2008;372(9653):1894–1905.
   PubMed Web of Science ®Google Scholar
• Rolland M, Tovanabutra S, Frahm N, et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med. 2011;17(3):366–371.
   PubMed Web of Science ®Google Scholar
• Iaccino E, Schiavone M, Fiume G, et al. The aftermath of the Merck’s HIV vaccine trial. Retrovirology. 2008;5(1):56.
   PubMed Web of Science ®Google Scholar
• Duerr A, Huang Y, Buchbinder S, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis. 2012;206(2):158–266.
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–2220.
   PubMed Web of Science ®Google Scholar
• Prentice HA, Tomaras GD, Geraghty DE, et al. HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. Sci Trans Med. 2015;7(296):296ra112–296ra112.
   Web of Science ®Google Scholar
• Corey L, Gilbert PB, Tomaras GD, et al. Immune correlates of vaccine protection against HIV-1 acquisition. Sci Trans Med. 2015;7(310):310rv317–310rv317.
   Web of Science ®Google Scholar
• Chung AW, Ghebremichael M, Robinson H, et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Trans Med. 2014;6(228):228ra238–228ra238.
   Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275–1286.
   PubMed Web of Science ®Google Scholar
• Kastenmüller W, Kastenmüller K, Kurts C, et al. Dendritic cell-targeted vaccines – hope or hype? Nat Rev Immunol. 2014;14(10):705–711.
   PubMed Web of Science ®Google Scholar
• Altfeld M, Fadda L, Frleta D, et al. DCs and NK cells: critical effectors in the immune response to HIV-1. Nat Rev Immunol. 2011;11(3):176–186.
   PubMed Web of Science ®Google Scholar
• Posch W, Lass-Flörl C, Wilflingseder D. Role of dendritic cell subsets on HIV-specific immunity. Rijeka: INTECH Open Access Publisher; 2013.
   Google Scholar
• Dutertre C-A, Wang L-F, Ginhoux F. Aligning bona fide dendritic cell populations across species. Cell Immunol. 2014;291(1):3–10.
   PubMed Web of Science ®Google Scholar
• Schlitzer A, Ginhoux F. Organization of the mouse and human DC network. Curr Opin Immunol. 2014;26:90–99.
   PubMed Web of Science ®Google Scholar
• Poulin LF, Salio M, Griessinger E, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cells. J Exp Med. 2010;207(6):1261–1271.
   PubMed Web of Science ®Google Scholar
• Shortman K, Lahoud MH, Caminschi I. Improving vaccines by targeting antigens to dendritic cells. Exp Mol Med. 2009;41(2):61–66.
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Zeelenberg IS, Cruz LJ, et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood. 2011;118(26):6836–6844.
   PubMed Web of Science ®Google Scholar
• Climent N, Munier S, Piqué N, et al. Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses. Vaccine. 2014;32(47):6266–6276.
   PubMed Web of Science ®Google Scholar
• Climent N, Pavot V, García F, et al. Co-delivery of antigen p24 and NOD-ligands by PLA nanoparticles to human dendritic cells promote highly functional HIV-1-specific T-cell responses. AIDS Res Hum Retroviruses. 2014;30(S1):A240–A241.
   Web of Science ®Google Scholar
• Lebel M-È, Daudelin J-F, Chartrand K, et al. Nanoparticle adjuvant sensing by TLR7 enhances CD8+ T cell–mediated protection from Listeria monocytogenes infection. J Immunol. 2014;192(3):1071–1078.
   PubMed Web of Science ®Google Scholar
• Hanson MC, Crespo MP, Abraham W, et al. Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants. J Clin Invest. 2015;125(125 (6)):2532–2546.
   PubMed Web of Science ®Google Scholar
• Lynn GM, Laga R, Darrah PA, et al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat Biotechnol. 2015;33(11):1201–1210.
   PubMed Web of Science ®Google Scholar
• Sun B, Ji Z, Liao Y-P, et al. Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles. ACS Nano. 2013;7(12):10834–10849.
   PubMed Web of Science ®Google Scholar
• Thomas SN, van der Vlies AJ, O’Neil CP, et al. Engineering complement activation on polypropylene sulfide vaccine nanoparticles. Biomaterials. 2011;32(8):2194–2203.
   PubMed Web of Science ®Google Scholar
• Shima F, Akagi T, Uto T, et al. Manipulating the antigen-specific immune response by the hydrophobicity of amphiphilic poly (γ-glutamic acid) nanoparticles. Biomaterials. 2013;34(37):9709–9716.
   PubMed Web of Science ®Google Scholar
• Moyano DF, Goldsmith M, Solfiell DJ, et al. Nanoparticle hydrophobicity dictates immune response. J Am Chem Soc. 2012;134(9):3965–3967.
   PubMed Web of Science ®Google Scholar
• Williams GR, Fierens K, Preston SG, et al. Immunity induced by a broad class of inorganic crystalline materials is directly controlled by their chemistry. J Exp Med. 2014;211(6):1019–1025.
   PubMed Web of Science ®Google Scholar
• Niikura K, Matsunaga T, Suzuki T, et al. Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo. ACS Nano. 2013;7(5):3926–3938.
   PubMed Web of Science ®Google Scholar
• Dykman L, Khlebtsov N. Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem Soc Rev. 2012;41(6):2256–2282.
   PubMed Web of Science ®Google Scholar
• Xu L, Liu Y, Chen Z, et al. Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment. Nano Lett. 2012;12(4):2003–2012.
   PubMed Web of Science ®Google Scholar
• le Guével X, Palomares F, Torres MJ, et al. Nanoparticle size influences the proliferative responses of lymphocyte subpopulations. RSC Adv. 2015;5(104):85305–85309.
   Web of Science ®Google Scholar
• Tomić S, Đokić J, Vasilijić S, et al. Size-dependent effects of gold nanoparticles uptake on maturation and antitumor functions of human dendritic cells in vitro. PLOS One. 2014;9(5):e96584.
   PubMed Web of Science ®Google Scholar
• Albanese A, Tang PS, Chan WCW. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14:1–16.
   PubMed Web of Science ®Google Scholar
• Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine. 2012;7:5577.
   PubMed Web of Science ®Google Scholar
• Zhao L, Seth A, Wibowo N, et al. Nanoparticle vaccines. Vaccine. 2014;32(3):327–337.
   PubMed Web of Science ®Google Scholar
• Foged C, Brodin B, Frokjaer S, et al. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm. 2005;298(2):315–322.
   PubMed Web of Science ®Google Scholar
• Kim H, Uto T, Akagi T, et al. Amphiphilic poly (amino acid) nanoparticles induce size‐dependent dendritic cell maturation. Adv Funct Mater. 2010;20(22):3925–3931.
   Web of Science ®Google Scholar
• Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine delivery systems: size matters. Aaps J. 2013;15(1):85–94.
   PubMed Web of Science ®Google Scholar
• Wischke C, Borchert -H-H, Zimmermann J, et al. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J Control Release. 2006;114(3):359–368.
   PubMed Web of Science ®Google Scholar
• Thiele L, Merkle HP, Walter E. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm Res. 2003;20(2):221–228.
   PubMed Web of Science ®Google Scholar
• Lunov O, Syrovets T, Loos C, et al. Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line. ACS Nano. 2011;5(3):1657–1669.
   PubMed Web of Science ®Google Scholar
• Le Guével X, Perrez Perrino M, Fernández TD, et al. Multivalent glycosylation of fluorescent gold nanoclusters promotes increased human dendritic cell targeting via multiple endocytic pathways. ACS Appl Mater Interfaces. 2015;7(37):20945–20956.
   PubMed Web of Science ®Google Scholar
• Joffre OP, Segura E, Savina A, et al. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12(8):557–569.
   PubMed Web of Science ®Google Scholar
• Tel J, Sittig SP, Blom RAM, et al. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J Immunol. 2013;191(10):5005–5012.
   PubMed Web of Science ®Google Scholar
• Segura E, Durand M, Amigorena S. Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ–resident dendritic cells. J Exp Med. 2013;210(5):1035–1047.
   PubMed Web of Science ®Google Scholar
• Reuter A, Panozza SE, Macri C, et al. Criteria for dendritic cell receptor selection for efficient antibody-targeted vaccination. J Immunol. 2015;194(6):2696–2705.
   PubMed Web of Science ®Google Scholar
• Mintern JD, Percival C, Kamphuis MMJ, et al. Targeting dendritic cells: the role of specific receptors in the internalization of polymer capsules. Adv Healthc. 2013;2(7):940–944.
   PubMed Web of Science ®Google Scholar
• Caminschi I, Proietto AI, Ahmet F, et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood. 2008;112(8):3264–3273.
   PubMed Web of Science ®Google Scholar
• Idoyaga J, Lubkin A, Fiorese C, et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci USA. 2011;108(6):2384–2389.
   PubMed Web of Science ®Google Scholar
• Li J, Ahmet F, Sullivan LC, et al. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non‐human primates. Eur J Immunol. 2015;45(3):854–864.
   PubMed Web of Science ®Google Scholar
• Sehgal K, Ragheb R, Fahmy TM, et al. Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15–dependent DC crosstalk. J Immunol. 2014;193(5):2297–2305.
   PubMed Web of Science ®Google Scholar
• Bertrand N, Leroux J-C. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J Control Release. 2012;161(2):152–163.
   PubMed Web of Science ®Google Scholar
• Perry JL, Reuter KG, Kai MP, et al. PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett. 2012;12(10):5304–5310.
   PubMed Web of Science ®Google Scholar
• Yang Q, Jones SW, Parker CL, et al. Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation. Mol Pharm. 2014;11(4):1250–1258.
   PubMed Web of Science ®Google Scholar
• Cui J, De Rose R, Alt K, et al. Engineering poly(ethylene glycol) particles for improved biodistribution. ACS Nano. 2015;9(2):1571–1580.
   PubMed Web of Science ®Google Scholar
• Segura E, Valladeau-Guilemond J, Donnadieu M-H, et al. Characterization of resident and migratory dendritic cells in human lymph nodes. J Exp Med. 2012;209(4):653–660.
   PubMed Web of Science ®Google Scholar
• Thomas SN, Schudel A. Overcoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug delivery. Curr Opin Chem Eng. 2015;7:65–74.
   PubMed Web of Science ®Google Scholar
• Liu H, Moynihan KD, Zheng Y, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507(7493):519–522.
   PubMed Web of Science ®Google Scholar
• Iwasaki A. Antiviral immune responses in the genital tract: clues for vaccines. Nat Rev Immunol. 2010;10(10):699–711.
   PubMed Web of Science ®Google Scholar
• Woodrow KA, Bennett KM, Lo DD. Mucosal vaccine design and delivery. Annu Rev Biomed Eng. 2012;14:17–46.
   PubMed Web of Science ®Google Scholar
• Ensign LM, Tang BC, Wang -Y-Y, et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Trans Med. 2012;4(138):138ra179–138ra179.
   Google Scholar
• Yu T, Wang -Y-Y, Yang M, et al. Biodegradable mucus-penetrating nanoparticles composed of diblock copolymers of polyethylene glycol and poly (lactic-co-glycolic acid). Drug Deliv Transl Res. 2012;2(2):124–128.
   Web of Science ®Google Scholar
• Lai SK, Suk JS, Pace A, et al. Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus. Biomaterials. 2011;32(26):6285–6290.
   PubMed Web of Science ®Google Scholar
• Suk JS, Kim AJ, Trehan K, et al. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. J Control Release. 2014;178:8–17.
   PubMed Web of Science ®Google Scholar
• Maisel K, Ensign L, Reddy M, et al. Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J Control Release. 2015;197:48–57.
   PubMed Web of Science ®Google Scholar
• Ensign LM, Lai SK, Wang -Y-Y, et al. Pretreatment of human cervicovaginal mucus with pluronic F127 enhances nanoparticle penetration without compromising mucus barrier properties to herpes simplex virus. Biomacromolecules. 2014;15(12):4403–4409.
   PubMed Web of Science ®Google Scholar
• Mastorakos P, da Silva AL, Chisholm J, et al. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy. Proc Natl Acad Sci USA. 2015;112(28):8720–8725.
   PubMed Web of Science ®Google Scholar
• Xie Z, Ji Z, Zhang Z, et al. Adenoviral vectors coated with cationic PEG derivatives for intravaginal vaccination against HIV-1. Biomaterials. 2014;35(27):7896–7908.
   PubMed Web of Science ®Google Scholar
• Coco R, Plapied L, Pourcelle V, et al. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int J Pharm. 2013;440(1):3–12.
   PubMed Web of Science ®Google Scholar
• Baggaley RF, White RG, Boily M-C. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol. 2010;39(4):1048–1063.
   PubMed Web of Science ®Google Scholar
• Tan H-X, Kent SJ, De Rose R. Contemporary HIV vaccines: tissue resident T-cells and strategies to prevent mucosal infection. Curr Top Med Chem. 2015. PMID 26324042.
   Web of Science ®Google Scholar
• Ramanathan R, Park J, Hughes SM, et al. Effect of mucosal cytokine administration on selective expansion of vaginal dendritic cells to support nanoparticle transport. Am J Reprod Immunol. 2015;74(4):333–344.
   PubMed Web of Science ®Google Scholar
• Granelli-Piperno A, Shimeliovich I, Pack M, et al. HIV-1 selectively infects a subset of nonmaturing BDCA1-positive dendritic cells in human blood. J Immunol. 2006;176(2):991–998.
   PubMed Web of Science ®Google Scholar
• Gringhuis SI, van der Vlist M, van den Berg LM, et al. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol. 2010;11(5):419–426.
   PubMed Web of Science ®Google Scholar
• Manches O, Frleta D, Bhardwaj N. Dendritic cells in progression and pathology of HIV infection. Trends Immunol. 2014;35(3):114–122.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang L, Liu Y, et al. Immune responses to vaccines involving a combined antigen–nanoparticle mixture and nanoparticle-encapsulated antigen formulation. Biomaterials. 2014;35(23):6086–6097.
   PubMed Web of Science ®Google Scholar
• Liard C, Munier S, Arias M, et al. Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine. 2011;29(37):6379–6391.
   PubMed Web of Science ®Google Scholar
• Klein F, Mouquet H, Dosenovic P, et al. Antibodies in HIV-1 vaccine development and therapy. Science. 2013;341(6151):1199–1204.
   PubMed Web of Science ®Google Scholar
• Chen J, Kovacs JM, Peng H, et al. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. Science. 2015;349(6244):191–195.
   PubMed Web of Science ®Google Scholar
• Sanders RW, van Gils MJ, Derking R, et al. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science. 2015;349(6244):aac4223.
   PubMed Web of Science ®Google Scholar
• Klein JS, Bjorkman PJ. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog. 2010;6(5):e1000908.
   PubMed Web of Science ®Google Scholar
• Schiller J, Chackerian B. Why HIV virions have low numbers of envelope spikes: implications for vaccine development. PLoS Pathog. 2014;10(8):e1004254.
   PubMed Web of Science ®Google Scholar
• Pejawar-Gaddy S, Kovacs JM, Barouch DH, et al. Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant env trimers in HIV vaccination. Bioconjugate Chem. 2014;25(8):1470–1478.
   PubMed Web of Science ®Google Scholar
• Verkoczy L, Kelsoe G, Haynes BF. HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog. 2014;10(5):e1004073.
   PubMed Web of Science ®Google Scholar
• Wahome N, Pfeiffer T, Ambiel I, et al. Conformation‐specific display of 4E10 and 2F5 epitopes on self‐assembling protein nanoparticles as a potential HIV vaccine. Chem Biol Drug Des. 2012;80(3):349–357.
   PubMed Web of Science ®Google Scholar
• Hanson MC, Abraham W, Crespo MP, et al. Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides. Vaccine. 2015;33(7):861–868.
   PubMed Web of Science ®Google Scholar
• Leaman DP, Lee JH, Ward AB, et al. Immunogenic display of purified chemically crosslinked HIV-1 spikes. J Virol. 2015;JVI:03738–03714.
   Google Scholar
• Chung AW, Kumar MP, Arnold KB, et al. Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. Cell. 2015;163(4):988–998.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Alter G, Broge T, et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science. 2015;349(6245):320–324.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Klein F, Pietzsch J, et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014;158(6):1243–1253.
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007;449(7158):101–104.
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Schmitz N, Storni T, et al. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004;172(9):5598–5605.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Tan GS, Palese P, et al. Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc [gamma] R interactions for protection against influenza virus in vivo. Nat Med. 2014;20(2):143–151.
   PubMed Web of Science ®Google Scholar
• Yassine HM, Boyington JC, McTamney PM, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med. 2015;21(9):1065–1070.
   PubMed Web of Science ®Google Scholar
• Beck Z, Matyas GR, Jalah R, et al. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Vaccine. 2015;33(42):5578–5587.
   PubMed Web of Science ®Google Scholar
• Keller S, Wilson JT, Patilea GI, et al. Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8+ T cell responses. J Control Release. 2014;191:24–33.
   PubMed Web of Science ®Google Scholar
• Benjaminsen RV, Mattebjerg MA, Henriksen JR, et al. The possible “proton sponge” effect of polyethylenimine (PEI) does not include change in lysosomal pH. Mol Ther. 2013;21(1):149–157.
   PubMed Web of Science ®Google Scholar
• Chen J, Li Z, Huang H, et al. Improved antigen cross-presentation by polyethyleneimine-based nanoparticles. Int J Nanomedicine. 2011;6:77–84.
   PubMed Web of Science ®Google Scholar
• Qi L, Shao W, Shi D. JAM-2 siRNA intracellular delivery and real-time imaging by proton-sponge coated quantum dots. J Mater Chem B. 2013;1(5):654–660.
   Web of Science ®Google Scholar
• Varkouhi AK, Scholte M, Storm G, et al. Endosomal escape pathways for delivery of biologicals. J Control Release. 2011;151(3):220–228.
   PubMed Web of Science ®Google Scholar
• Sayers EJ, Cleal K, Eissa NG, et al. Distal phenylalanine modification for enhancing cellular delivery of fluorophores, proteins and quantum dots by cell penetrating peptides. J Control Release. 2014;195:55–62.
   PubMed Web of Science ®Google Scholar
• Ye S-F, Tian M-M, Wang T-X, et al. Synergistic effects of cell-penetrating peptide Tat and fusogenic peptide HA2-enhanced cellular internalization and gene transduction of organosilica nanoparticles. Nanomedicine: NBM. 2012;8(6):833–841.
   PubMed Web of Science ®Google Scholar
• Tang J, Yin R, Tian Y, et al. A novel self-assembled nanoparticle vaccine with HIV-1 Tat 49-57/HPV16 E7 49-57 fusion peptide and GM-CSF DNA elicits potent and prolonged CD8+ T cell-dependent anti-tumor immunity in mice. Vaccine. 2012;30(6):1071–1082.
   PubMed Web of Science ®Google Scholar
• Cheng CJ, Tietjen GT, Saucier-Sawyer JK, et al. A holistic approach to targeting disease with polymeric nanoparticles. Nat Rev Drug Discov. 2015;14(4):239–247.
   PubMed Web of Science ®Google Scholar
• Liu D, Auguste DT. Cancer targeted therapeutics: from molecules to drug delivery vehicles. J Control Release. 2015;219:632–643.
   PubMed Web of Science ®Google Scholar
• Roy U, Rodríguez J, Barber P, et al. The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials. Nanomedicine. 2015;10(24):3597–3609.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials Database: NCT02549040. [cited 2015 Nov 7]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02549040.
   Google Scholar
• ClinicalTrials Database: NCT02165202. [cited 2015 Nov 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT02165202.
   Google Scholar
• ClinicalTrials Database: NCT02076178. [cited 2015 Nov 7]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02076178
   Google Scholar
• ClinicalTrials Database: NCT00712530. [cited 2015 Nov 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT00712530.
   Google Scholar
• ClinicalTrials Database: NCT00711230. [cited 2015 Nov 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT00711230.
   Google Scholar
• Deeks SG, Autran B, Berkhout B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012;12(8):607–614.
   PubMed Web of Science ®Google Scholar
• Deeks SG. HIV: shock and kill. Nature. 2012;487(7408):439–440.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science. 2014;345(6193):169–174.
   PubMed Web of Science ®Google Scholar
• Tinkle S, McNeil SE, Mühlebach S, et al. Nanomedicines: addressing the scientific and regulatory gap. Ann New York Acad Sci. 2014;1313(1):35–56.
   PubMed Web of Science ®Google Scholar